Oral administration of FT-4202 increases Hb and improves RBC parameters in BERK mice following FT-4202 administration. Total bilirubin (A) and LDH (B) concentrations in plasma collected from control and FT-4202 BERK mice after 2 weeks of placebo vs FT-4202 administration. Each symbol represents an individual animal: n = 12 control BERK mice and n = 13 FT-4202 BERK mice. (C) Half-life of RBCs in FT-4202 and control BERK mice, as determined by in vivo biotin labeling. Each symbol represents the RBC half-life of an individual mouse: n = 10 control BERK mice and n = 7 FT-4202 BERK mice. (D-G) Peripheral blood analysis at day 0 (D0) and after 2 weeks of placebo vs FT-4202 treatment (D14) showing RBC counts (D), Hb (E), hematocrit (F), and percentage of reticulocytes (G) in FT-4202 BERK as compared with control BERK mice. (D-G) n = 7 control BERK and n = 8 FT-4202 BERK. Comparison of day 0 vs day 14 was made using the paired Student t test and comparison between control and FT-4202 groups was made using the unpaired Student t test: **P < .01, ***P < .001, ****P < .0001.